One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Single-Cell Immunology in Cardiovascular Medicine: Do We Know Yet What We Do Not Know?
Susanne Sattler
doi : 10.1161/CIRCULATIONAHA.121.055763
Circulation. 2021;144:843–844
Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure
Andreas Rillig, Christina Magnussen, Ann-Kathrin Ozga, Anna Suling, Axel Brandes, Günter Breithardt, A. John Camm, Harry J.G.M. Crijns, Lars Eckardt, Arif Elvan, Andreas Goette, Michele Gulizia, Laurent Haegeli, Hein Heidbuchel, Karl-Heinz Kuck, Andre Ng, Lukasz Szumowski, Isabelle van Gelder, Karl Wegscheider, Paulus Kirchhof
doi : 10.1161/CIRCULATIONAHA.121.056323
Circulation. 2021;144:845–858
Even on optimal therapy, many patients with heart failure and atrial fibrillation experience cardiovascular complications. Additional treatments are needed to reduce these events, especially in patients with heart failure and preserved left ventricular ejection fraction.
Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction
Nathan Mewton, François Roubille, Didier Bresson, Cyril Prieur, Claire Bouleti, Thomas Bochaton, Fabrice Ivanes, Olivier Dubreuil, Loïc Biere, Ahmad Hayek, François Derimay, Mariama Akodad, Benjamin Alos, Lamis Haider, Naoual El Jonhy, Rachel Daw, Charles De Bourguignon, Carole Dhelens, Gérard Finet, Eric Bonnefoy-Cudraz, Gabriel Bidaux, Florent Boutitie, Delphine Maucort-Boulch, Pierre Croisille, Gilles Rioufol, Fabrice Prunier, Denis Angoulvant, on behalf of the COVERT-MI Study Investigators
doi : 10.1161/CIRCULATIONAHA.121.056177
Circulation. 2021;144:859–869
Inflammation is a key factor of myocardial damage in reperfused ST-segment–elevation myocardial infarction. We hypothesized that colchicine, a potent anti-inflammatory agent, may reduce infarct size (IS) and left ventricular (LV) remodeling at the acute phase of ST-segment–elevation myocardial infarction.
Red Blood Cell and Endothelial eNOS Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure
Francesca Leo, Tatsiana Suvorava, Sophia K. Heuser, Junjie Li, Anthea LoBue, Frederik Barbarino, Eugenia Piragine, Rebekka Schneckmann, Beate Hutzler, Miranda E. Good, Bernadette O. Fernandez, Lukas Vornholz, Stephen Rogers, Allan Doctor, Maria Grandoch, Johannes Stegbauer, Eddie Weitzberg, Martin Feelisch, Jon O. Lundberg, Brant E. Isakson, Malte Kelm, Miriam M. Cortese-Krott
doi : 10.1161/CIRCULATIONAHA.120.049606
Circulation. 2021;144:870–889
Current paradigms suggest that nitric oxide (NO) produced by endothelial cells (ECs) through endothelial nitric oxide synthase (eNOS) in the vessel wall is the primary regulator of blood flow and blood pressure. However, red blood cells (RBCs) also carry a catalytically active eNOS, but its role is controversial and remains undefined. This study aimed to elucidate the functional significance of RBC eNOS compared with EC eNOS for vascular hemodynamics and nitric oxide metabolism.
Endothelium Seeing Red: Should We Redefine eNOS as the Endothelial and Erythrocytic NOS?
Mark T. Gladwin
doi : 10.1161/CIRCULATIONAHA.121.055679
Circulation. 2021;144:890–892
Interleukin-1? Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease
Stefan J. Schunk, Sarah Triem, David Schmit, Stephen Zewinger, Tamim Sarakpi, Ellen Becker, Gregor Hütter, Selina Wrublewsky, Fabienne Küting, Mathias Hohl, Dalia Alansary, Leticia Prates Roma, Peter Lipp, Julia Möllmann, Michael Lehrke, Matthias W. Laschke, Michael D. Menger, Rafael Kramann, Peter Boor, Willi Jahnen-Dechent, Winfried März, Michael Böhm, Ulrich Laufs, Barbara A. Niemeyer, Danilo Fliser, Emmanuel Ampofo, Thimoteus Speer
doi : 10.1161/CIRCULATIONAHA.121.053547
Circulation. 2021;144:893–908
Cardiovascular diseases and chronic kidney disease (CKD) are highly prevalent, aggravate each other, and account for substantial mortality. Both conditions are characterized by activation of the innate immune system. The alarmin interleukin-1? (IL-1?) is expressed in a variety of cell types promoting (sterile) systemic inflammation. The aim of the present study was to examine the role of IL-1? in mediating inflammation in the setting of acute myocardial infarction (AMI) and CKD.
Atrial-Specific LKB1 Knockdown Represents a Novel Mouse Model of Atrial Cardiomyopathy With Spontaneous Atrial Fibrillation
Mohit M. Hulsurkar, Satadru K. Lahiri, Oliver Moore, Lucia M. Moreira, Issam Abu-Taha, Markus Kamler, Dobromir Dobrev, Stanley Nattel, Svetlana Reilly, Xander H.T. Wehrens
doi : 10.1161/CIRCULATIONAHA.121.055373
Circulation. 2021;144:909–912
Letter by Lother et al Regarding Article, “Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes”
Achim Lother, Christoph Bode, Lutz Hein
doi : 10.1161/CIRCULATIONAHA.121.053660
Circulation. 2021;144:e201
Response by Filippatos et al to Letter Regarding Article, “Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes”
Gerasimos Filippatos, Rajiv Agarwal, George Bakris, Stefan Anker, and on behalf of FIDELIO-DKD Committees and Investigators
doi : 10.1161/CIRCULATIONAHA.121.055066
Circulation. 2021;144:e202–e203
